Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Cisplatin Induction in NSCLC
NCT00432315Phase 2Completed
- Sponsor
- Sanofi
- Start
- May 2001
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of docetaxel in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Sanofi. Primary endpoint: Objective Response Rate. Started May 2001; status: completed.
02
Drugs
docetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00432315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00432315.